231.78 0.00 (0.00%)
After hours: 4:58PM EDT
|Bid||231.32 x 800|
|Ask||231.30 x 800|
|Day's Range||227.66 - 232.95|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||10.02|
|Earnings Date||Jul 22, 2019 - Jul 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.79|
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.
MISSISSAUGA, ON , June 13, 2019 /CNW/ - Biogen Canada is pleased to announce that patients in Ontario living with spinal muscular atrophy (SMA) now have broader publicly funded access to SPINRAZA™ (nusinersen), the first and only treatment approved in Canada for SMA.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high.
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.Source: Zynerba PharmaceuticalsThe stock was up 8% in pre-market trading and there's potential for this name to run even further once investors catch wind of it. We're seeing that play out now, with shares up 18% in Tuesday morning trading.With a market capitalization just under $250 million, it's not a well-known player like Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG). In the same light, it's not even a well-known cannabis stock, like Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB).InvestorPlace - Stock Market News, Stock Advice & Trading TipsZynerba was issued U.S. Patent No. 10,314,792, which is titled, "Treatment of Autism Spectrum Disorder with Cannabidiol" and runs through 2038. So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The PatentZynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. I say "potential" because there's still a lot of work and progress needed before this becomes a staple in the medicine cabinet, so to say. * 7 Dark Horse Stocks Winning the Race in 2019 The patented treatment "includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol." It was granted during the enrollment period of a Phase 2 BRIGHT study, which is intended to evaluate "the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder."Will it work? At this stage it's impossible to say, but there is promise. GW Pharmaceuticals (NASDAQ:GWPH) has successfully gained traction -- even here in the U.S. -- with its cannabidiol treatment for epileptic seizures. So if Zynerba can show similar successes with its treatment, it may open the door to other possible treatments in the future using its Zygel product. Trading ZYNE Stock Click to Enlarge The big boost in ZYNE stock comes as little surprise. After all, it's got all the right buzzwords working in its favor, even if the company has good intentions. Wall Street latches to these trends and investors aren't afraid to jump on board if they think there's opportunity. That's even as Phase-2 testing has yet to begin.ZYNE stock chart is one of only a few that could make a double-digit gain look fairly modest. Above you can see how it moved over downtrend resistance (blue line) on Monday. Now it's pushing through $13, as well as the 20-day moving average.Can this thing ignite through $14 and tag its 2019 high near $16.50? Yes, it can. There's no guarantee that it will, but these sort of momentum boosters can give a huge shot in the arm to small-cap stocks.Whether that justifies a move this powerful, ZYNE stock investors certainly have a reason to be excited. But there's a lot of room on the upside before Zynerba stock exhausts itself.On the downside, I want to see $11 to $11.50 hold as support.This marks the 50-day moving average (which is trending higher) as well as the 38.2% retracement. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday's gains. Bottom Line on ZYNE StockNorth of $13 and the 20-day would be best, but let's see how it trades throughout the day and the rest of this week.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $14.65 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
Biogen stock dipped Thursday after the biotech company unveiled plans for its ALS treatments. Analysts were largely unimpressed, and don't expect the drugs to bring in much in sales.
In a webcast, the company outlined a strategy that focuses in the near term on rarer forms of amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Growth driversSince the second quarter of 2016, Gilead Sciences (GILD) has been reporting major YoY (year-over-year) revenue declines, mainly due to its lower HCV
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)MS revenue performance in the first quarterIn the first quarter, Biogen (BIIB) reported MS (multiple sclerosis) franchise revenue of ~$2.1 billion including
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Failed programOn March 21, Biogen (BIIB) issued a press release announcing the discontinuation of its Phase 3 trials ENGAGE and EMERGE evaluating its leading
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
Biogen Inc. (BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well tolerated in people with relapsing multiple sclerosis (MS). Diroximel fumarate, a novel oral fumarate candidate in development with Alkermes plc (ALKS), is under review with the U.S. Food and Drug Administration with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019.
Biogen stock has been through the wringer in 2019, and some think an acquisition could get it back on track. Here are several potential takeover targets.